Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07D

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/232557METHOD OF MAKING COCOA BUTTER-DERIVED PRODUCTS CONTAINING CANNABINOIDS
WO 26.11.2020
Int.Class A23G 1/38
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
1Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
30Cocoa products, e.g. chocolate; Substitutes therefor
32characterised by the composition
36characterised by the fats used
38Cocoa butter substitutes
Appl.No PCT/CA2020/050692 Applicant CANOPY GROWTH CORPORATION Inventor GEILING, Ben
The present technology generally relates to methods of making cocoa butter-derived products that comprise cannabinoids. The present technology further generally relates to cocoa butter-derived products resulting from such methods.
2.WO/2020/232807NAPHTHOQUINONE FUSED TRIAZOLE DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF
WO 26.11.2020
Int.Class C07D 249/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
249Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
16condensed with carbocyclic rings or ring systems
22Naphthotriazoles
Appl.No PCT/CN2019/095288 Applicant GUANGZHOU UNIVERSITY OF CHINESE MEDICINE (GUANGZHOU ACADEMY OF CHINESE MEDICINE) Inventor LIU, Jiawei
Provided are a naphthoquinone fused triazole derivative, preparation method and application thereof. The naphthoquinone fused triazole derivative has a structure represented by the following formula (I), wherein X is C or N; R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8 are each independently any one of hydrogen, halogen, hydroxyl, cyano, sulfydryl, amino, nitro, nitroso, alkyl, alkoxy, ester group, carboxyl and sulfonyl. Also provided is the application of the naphthoquinone fused triazole derivative or a pharmaceutically acceptable salt or hydrate thereof in preparation of a medicament for treating a disease with abnormal signal transduction of STAT3.
3.WO/2020/233677PROCESS FOR PREPARING AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS
WO 26.11.2020
Int.Class C07D 235/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
235Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
02condensed with carbocyclic rings or ring systems
Appl.No PCT/CN2020/091603 Applicant BEIGENE (BEIJING) CO., LTD. Inventor WANG, Hexiang
Disclosed herein is a process for preparing amide-substituted imidazo compounds. In particular, disclosed herein is the process for preparing certain amide-substituted imidazo compounds that are useful for inhibiting indoleamine 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.
4.WO/2020/234277CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON S DISEASE
WO 26.11.2020
Int.Class A61K 31/4741
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4741condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
Appl.No PCT/EP2020/063918 Applicant H. LUNDBECK A/S Inventor JØRGENSEN, Morten
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
5.WO/2020/234817POLYMORPHIC FORMS OF APALUTAMIDE AND ITS PREPARATION THEREOF
WO 26.11.2020
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No PCT/IB2020/054815 Applicant LAURUS LABS LIMITED Inventor THAIMATTAM, Ram
The present invention relates to novel crystalline polymorphic forms of apalutamide. The present invention also relates to processes for preparation of amorphous form of apalutamide and pharmaceutical composition containing the same.
6.WO/2020/235587TANDOSPIRONE DERIVATIVE
WO 26.11.2020
Int.Class C07D 209/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
56Ring systems containing three or more rings
58- or -condensed
724,7-Endo-alkylene-iso-indoles
76with oxygen atoms in positions 1 and 3
Appl.No PCT/JP2020/019911 Applicant NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA Inventor KONDO Takashi
A compound represented by formula (1) or a pharmaceutically acceptable salt thereof can be used as an active ingredient of a drug for central nervous system diseases or as a candidate compound for a precursor of said active ingredient. In formula (1), R1, R2, and R3 each independently represent a substance selected from the group consisting of a hydrogen atom, a hydroxy group, and an alkoxy group having 1-6 carbon atoms, and at least one of R1, R2, and R3 is a hydroxy group.
7.WO/2020/236947SOLID STATE FORMS
WO 26.11.2020
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/US2020/033831 Applicant AMGEN INC. Inventor CHAVES, Mary
The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous,hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
8.WO/2020/237047CRYSTALLINE SALT FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
WO 26.11.2020
Int.Class C07D 215/36
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
215Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
02having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
16with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
36Sulfur atoms
Appl.No PCT/US2020/033992 Applicant AGIOS PHARMACEUTICALS, INC. Inventor GROVE, Lisa M.
Provided herein are various crystalline salt forms of compound (I) represented by the following structural formula: Also provided are pharmaceutical compositions comprising the crystalline salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.
9.WO/2020/232526METHOD FOR ACETYLATION OF CANNABINOIDS
WO 26.11.2020
Int.Class C07D 311/80
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
311Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
02ortho- or peri-condensed with carbocyclic rings or ring systems
78Ring systems having three or more relevant rings
80Dibenzopyrans; Hydrogenated dibenzopyrans
Appl.No PCT/CA2019/051350 Applicant NEXTLEAF SOLUTIONS LTD Inventor PAL, Krupal Devendra
A process for producing THC-O-acetate using a succession of distillation, salting-out assisted liquid-liquid extractions (SALLEs), and solvent recovery techniques. Tetrahydrocannabinol (THC) in cannabis oil reacts with acetic anhydride under reflux to produce THC-O-acetate and acetic acid. The resulting crude product is distilled and subjected to a SALLE with hexane followed by a SALLE with petroleum ether, before being distilled again in order to obtain a refined, THC-O-acetate product.
10.WO/2020/233226B CRYSTAL FORM OF TETRAHYDROTHIENOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION AND APPLICATION
WO 26.11.2020
Int.Class C07D 495/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
495Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/CN2020/081091 Applicant CHENGDU SHIBEIKANG BIOMEDICAL TECHNOLOGY CO., LTD. Inventor CEN, Guodong
Disclosed in the present invention are a B crystal form of a tetrahydrothienopyridine compound having a structure as represented by formula I, a preparation method therefor, a composition and an application, for use in solving the problems in the prior art of lots of impurities, low content, bad crystal form stability, and inability to form a drug. The B crystal form uses Cu-Kα radiation, and X-ray powder diffraction expressed at a 2θ angle has characteristic peaks at 11.21±0.2°, 12.61±0.2°, 14.69±0.2°, 16.14±0.2°, 17.81±0.2°, 20.22±0.2°, and 22.10±0.2°. The B crystal form of the present invention has few of impurities, good stability, good crystallinity, and reproducibility, and is suitable for industrial production; moreover, the B crystal form has an unexpectedly stronger anti-ADP-induced platelet aggregation effect and better fluidity.